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Introduction  
 
Urea cycle disorders are inherited deficien-
cies of the enzymes involved in the cellular 
excretion of excess ammonia produced dur-
ing protein metabolism.  Hyperammonemia 
associated with these disorders is usually 
manifested by decreased level of conscious-
ness, irritability, seizures, vomiting, and poor 
feeding.  Although the majority of recog-
nized patients are children, a delayed presen-
tation is seen in patients with partial enzyme 
deficiency, including heterozygotes.  These 
patients become symptomatic in later child-
hood or adulthood.  Diagnoses of urea cycle 
defects (UCD) in the adult population have 
been reported.1-3  Often, the diagnosis only 
becomes apparent during times of increased 
metabolic stress, such as with acute or chron-
ic illness.  Prompt recognition and treatment 
are essential in determining the outcome of 
these patients.  We present a case of hyper-
ammonemic encephalopathy from a pre-
sumed urea cycle defect.  
 
Case Report 
 
We report a case of a 48-year-old woman 
with a history of bulimia and bipolar disorder  
 
 
who presented with a four week history of 
confusion and lethargy in the setting of a 
twenty-pound weight loss.  Per family, the 
patient began to exhibit poor recall and per-
sonality changes over the course of a year 
and had begun to lose weight over the previ-
ous 6 months.  In the week prior to admis-
sion, she had been speaking very little and 
was consuming only fluids.  In the ER, she 
was minimally responsive and appeared 
poorly groomed.  She had an initial lumbar 
puncture that was normal.  Her head CT 
showed scattered, patchy, ill-defined hypo-
densities in the white matter of both cerebral 
hemispheres, more than expected for the pa-
tient’s age.  Initial laboratory studies demon-
strated a low bicarbonate level, consistent 
with a non-anion gap metabolic acidosis, for 
which she was placed on bicarbonate drip. 
Her B12, folate, thiamine, TSH, and toxicol-
ogy screen were unremarkable with the ex-
ception of an ammonia level of 371 µmol/L 
(10-50 µmol/L).  There was no other evi-
dence of liver failure.  
 
Shortly after the patient's arrival, the patient 
experienced three episodes of non-sustained 
ventricular tachycardia and became obtund-
ed.  She was noted to have roving eye move-
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ments and posturing of all four limbs.  The 
patient received heavy sedation and anticon-
vulsants for presumed status epilepticus, 
which was later confirmed by EEG.  Her 
neurological exam was compromised by 
heavy sedation.  She did have a minimal gag 
reflex, but no other brainstem reflexes, no 
elicitable response to pain, and no response 
to plantar stimulation bilaterally.  Initial MRI 
brain revealed widespread restricted diffu-
sion in the insula and cerebral cortex, sug-
gestive of hypoxic-ischemic injury.   
 
Her acute clinical decompensation and high 
ammonia prompted extensive work up of her 
metabolic status, including amino acid defi-
ciencies.  Other causes of acute hyperammo-
nemia in adults were considered, such as ma-
lignancy, multiple myeloma, and valproate-
induced hyperammonemia.4  Her immunofix-
ation revealed an IgA lambda monoclonal 
band, but there was no evidence of multiple 
myeloma or cancer.  Her valproate level was 
less than 10, making this etiology unlikely.  
Less common causes, such as inborn and ac-
quired errors of metabolism, were further 
investigated.  A low carnitine level in the set-
ting of hyperammonemia, a high creatine ki-
nase (peripheral metabolism), a high triglyc-
eride level (ketosis), and low BUN (2-3mg/
dL) supported a metabolic defect and genet-
ics was consulted.  Quantitative amino acid  
Table 1: Quantitative amino acid panels. Abnormal values in red, HD = Hospital Day.  
 
Test Reference HD#3 HD#5 HD#7 
Taurine 25-80 18 µmol/L (L) 9 µmol/L (L) 7 µmol/L (L) 
Aspartic Acid 0-20 10 µmol/L 9 µmol/L 11 µmol/L 
Hydroxyproline 6-50 46 µmol/L 25 µmol/L 16 µmol/L 
Threonine 60-220 100 µmol/L 37 µmol/L (L) 71 µmol/L 
Serine 60-200 56 µmol/L (L) 21 µmol/L (L) 34 µmol/L (L) 
Allo-isoleucine 0 0 µmol/L 0 µmol/L 0 µmol/L 
Homocystine QBAA 0 0 µmol/L 0 µmol/L 0 µmol/L 
Glutamic Acid 10-120 46 µmol/L 44 µmol/L 36 µmol/L 
Glutamate 410-700 1054 µmol/L (H) 328 µmol/L (L) 376 µmol/L (L) 
Proline 110-500 521 µmol/L (H) 238 µmol/L 143 µmol/L 
Glycine 140-490 224 µmol/L 92 µmol/L (L) 152 µmol/L 
Alanine 240-600 283 µmol/L 160 µmol/L (L) 222 µmol/L (L) 
Citrulline 10-60 20 µmol/L 8 µmol/L (L) 3 µmol/L (L) 
Valine 140-350 88 µmol/L (L) 26 µmol/L (L) 55 µmol/L (L) 
Cystine 7-70 12 µmol/L 4 µmol/L (L) 5 µmol/L (L) 
Methionine 17-53 10 µmol/L (L) 3 µmol/L (L) 9 µmol/L (L) 
Isoleucine QBAA 30-130 13 µmol/L (L) 0 µmol/L (L) 13 µmol/L (L) 
Leucine 60-230 35 µmol/L (L) 21 µmol/L (L) 27 µmol/L (L) 
Tyrosine 30-120 17 µmol/L (L) 10 µmol/L (L) 13 µmol/L (L) 
Phenylalanine 30-80 23 µmol/L (L) 19 µmol/L (L) 24 µmol/L (L) 
Ornithine QBAA 20-135 82 µmol/L 22 µmol/L 69 µmol/L 
Lysine 80-250 234 µmol/L 91 µmol/L 155 µmol/L 
Histidine 50-130 96 µmol/L 64 µmol/L 69 µmol/L 
Arginine 40-160 27 µmol/L (L) 8 µmol/L (L) 21 µmol/L (L) 
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panels were obtained and the first three are 
shown in Table 1.  With successive panels, 
taurine, hydroxyproline, proline, threonine, 
serine, glycine, alanine, citrulline, valine, 
cystine, methionine, isoleucine, leucine, tyro-
sine, phenylalanine, and arginine were ob-
served to be low or downtrending overall. 
Aspartic acid, lysine, and histidine were con-
sistently normal.  Glutamate was initially ele-
vated and ornithine became elevated late. 
The patient’s amino acid panel (development 
of low citrulline and low arginine) indicated 
that she most likely had an ornithine trans-
carbamylase (OTC) or carbamoyl phosphate 
synthetase I (CPS I) dysfunction.  However, 
the patient did not exhibit orotic aciduria to 
support OTC deficiency and genetic testing 
from a liver biopsy failed to reveal any muta-
tions to support CPS I deficiency.  As a part 
of her treatment, she was given multiple dos-
es of lactulose but failed to improve clinical-
ly.  She was treated with Ammonul, an am-
monia-scavenging agent consisting of sodi-
um phenylacetate and sodium benzoate.5 Her 
ammonia level improved to the normal range 
within 24 hours. 
 
Follow-up diffusion-weighted MRI (Figure 
1a) and FLAIR images (Figure 1b) demon- 
 
strated decreased intensity in previously not-
ed areas and no new lesions, leading to the 
hypothesis that MRI findings were the result 
of hyperammonemia rather than due to glob-
al hypoxic-ischemic injury.6  Related to this 
finding, MR spectroscopy demonstrated 
peaks most strongly for glutamine rather than 
lactate, supporting glutamate toxicity as a 
result of a urea cycle defect as opposed to 
hypoxic-ischemic injury.  Genetic testing 
failed to identify mutations for OTC or CPS I 
deficiency, which are the most commonly 
occurring genetic deficiencies.  However, 
with the inability to detect variant polymor-
phisms as well as large deletions and dupli-
cations, the possibility of a urea cycle defect 
was still the likely diagnosis.  Due to the pa-
tient's poor neurological prognosis, her fami-
ly requested comfort measures only, and she 
subsequently expired.  
 
Discussion 
 
As described by our case, the presence of 
unexplained hyperammonemia raises the 
possibility of an inborn error of metabolism.  
Typically, with the urea cycle, glutamate is 
first combined with Acetyl CoA by N-
acetylglutamate synthetase (NAGS) to create 
Figure 1a: Diffusion-weighted MRI.  Figure 1b: FLAIR MRI.  
HD #8 HD #15 HD #9 HD #17 
 
Figure 1: Radiographic changes in response to Ammonul. The boxed area in the FLAIR imag-
es reflects the area of interest, the insular cortex, analyzed on MR spectroscopy.  
HD = Hospital Day.  
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N-acetylglutamate.  Ammonia is then incor-
porated into N-acetylglutamate by carbamoyl 
phosphate synthetase I (CPS I) to generate 
carbamoyl phosphate.  Ornithine transcar-
bamylase (OTC) then catalyzes a reaction 
between carbamoyl phosphate and ornithine 
to generate citrulline in the urea cycle.  The 
ammonium ion is later transferred to form 
urea and is excreted.  Deficiency in any five 
of the enzymes in the urea cycle results in the 
accumulation of ammonia which could be 
potentially fatal if untreated.7  Although usu-
ally seen in neonates, later cases of child-
hood and adulthood have been described.1-3  
The presentation can be atypical, with chron-
ic vomiting, developmental delay, seizure 
disorder, sleep disorders, or psychiatric ill-
nesses following increased protein intake or 
during periods of stress such as acute or 
chronic illness.1  
 
The most common deficiencies are N-
acetylglutamate synthetase (NAGS) deficien-
cy, carbamoyl phosphate synthetase I (CPS I) 
deficiency, and ornithine transcarbamylase 
(OTC) deficiency, all of which have an en-
zyme defect early in the urea cycle.  OTC 
and CPS deficiency patients may display a 
low citrulline and arginine level in the meta-
bolic panel, as in our patient.  Urine studies 
in an OTC patient typically show a high level 
of orotic acid, which is a by-product of the 
cycle and is made from carbamoyl phosphate 
when OTC is not available.  While our pa-
tient did not exhibit orotic aciduria, OTC is 
an X-linked disorder and can have a late 
presentation from carrier states in which 
there are varying amounts of residual en-
zyme activity.1  The amount of organic acids 
(orotic acids) in the urine may be difficult to 
detect in these patients because of the vary-
ing degree of enzymatic activity 
(lyonization).7,8  The OTC gene has been 
found to exhibit enormous variation.  More 
than 340 mutations have been identified in 
families in which there was clinical OTC de-
ficiency.9  A patient with CPS I deficiency 
(autosomal recessive) would likely demon-
strate mutation of the CPS I gene.  Although 
the mutation was not detected in the liver 
biopsy of our patient, this condition cannot 
be excluded, as altered transcriptional regula-
tion of CPS I expression by polymorphisms 
is possible and the genetic testing does not 
detect large heterozygous deletions, duplica-
tions, or mutations within the promoter or 
deep intronic regions.10  Lastly, a patient 
with NAGS deficiency would typically dis-
play a high alanine and glutamine level, 
which was not observed in our patient. 
 
An early recognition of the toxic effects of 
hyperammonemia and investigation into eti-
ology are critical for good prognosis.  If un-
treated, patients may develop increased intra-
cranial pressure, seizures and subclinical sei-
zures (40% of cases), and eventually cerebral 
herniation and fatal outcome.3  Our patient’s 
symptoms of confusion, lethargy, and weight 
loss are consistent with a progressive hyper-
ammonemic state.  Further, quantitative evi-
dence of continual elevation of ammonia was 
found.  Response to treatment with sodium 
phenylacetate and sodium benzoate 
(ammonia scavenging agents) in patients 
with urea cycle dysfunction can potentially 
reverse the toxic effects of ammonia.11 This 
patient’s ammonia level was reduced to the 
normal range within 24 hours, and she exhib-
ited radiographic improvement (Figure 1a 
and 1b).  Hyperammonemia of this etiology 
that is treated promptly has a good prognosis.  
Urea cycle defects are treatable with a low-
protein diet, amino acid supplementation, 
and/or liver transplant.12  Unfortunately, in 
this case, because of prolonged toxicity, the 
patient’s status epilepticus could not be re-
solved and she suffered a fatal outcome.  Our 
case provides emphasis that early recognition 
of hyperammonemic encephalopathy without 
evidence of liver failure should prompt in-
vestigation for a urea cycle defect.  
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Summary 
 
Although most commonly associated with 
infancy, urea cycle defects should be consid-
ered in adults with unexplained encephalopa-
thy and ammonia levels should be checked 
immediately.  The signs and symptoms may 
be vague and atypical but patients may pre-
sent with recurrent and fulminant presenta-
tions.  Specific metabolic testing and enzy-
matic or molecular confirmation are neces-
sary to establish the diagnosis but may not 
always be possible due to presently still un-
described mutations.  Early recognition and 
treatment with medication, dietary protein 
restrictions, and/or liver transplant can im-
prove long term outcome and prompt spe-
cialty care including neurology/genetics 
should be considered.  
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